|
Dear Ggg and Welcome New Members,
BioStem Technologies Delivers Solid Q3 Results, Expands Clinical Footprint, and Targets Nasdaq Uplisting with a $25.50 Zacks Price Target.
BioStem Technologies (OTC: BSEM) reported a resilient Q3 2025, generating $10.5 million in net revenue, $0.8 million in GAAP net income, and achieving its seventh consecutive quarter of positive adjusted EBITDA, coming in at $2.7 million.
Despite modest pricing-related revenue pressure, the company continues to demonstrate financial strength, supported by an 88.5% gross margin and a $27.2 million cash balance. Zacks Small Cap Research maintains a $25.50 price target, reflecting confidence in BioStem’s operational performance, expanding revenue channels, and maturing clinical portfolio.
Clinically, BioStem’s BioREtain® allografts are gaining meaningful traction. A published Level 1 randomized trial in diabetic foot ulcers showed significantly superior outcomes versus standard care, reinforcing competitive differentiation and supporting expanded reimbursement visibility.
With new penetration into VA and Medicaid programs, growing hospital and ASC opportunities, and a Nasdaq uplisting targeted for mid-2026, BioStem is positioning itself for long-term growth in a MedTech market that continues to benefit from strong demand, aging demographics, and underpenetrated regenerative-care needs.
See why BSEM may be well-timed for investors seeking exposure to high-growth MedTech.
|
